214 Autism & Microbiota Transfer Therapy – Adams

microbiota transfer therapy

 Autism & Fecal Microbiota Transfer Therapy – MTT – FMT – Update

James B. Adams, Ph.D., is a President’s Professor at Arizona State University, where he directs the autism/Asperger’s research program, though he originally taught chemical and materials engineering there. Dr. Adams also holds a post at the Southwest College of Naturopathic Medicine. He is also the president of the Autism Society of Greater Phoenix, the co-chair of the Autism Research Institute’s scientific advisory committee, and has received the Autism Service Award from the Greater Phoenix chapter of the Autism Society of America.

This CBJ/214 reveals a most interesting development in Autism Treatment directly related to gut microbiota and his research with FMTT Fecal Microbiota Transfer Therapy. Must listen!

Photo by Artak Petrosyan on Unsplash

Reference Details For MTT: Article Abstract

Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study.

Publication

Microbiome – Jan. 23, 2017

Author(s)

Dae-Wook Kang, James B. Adams, Ann C. Gregory, Thomas Borody, Lauren Chittick5,15, Alessio Fasano, Alexander Khoruts, Elizabeth Geis, Juan Maldonado, Sharon McDonough-Means, Elena L. Pollard, Simon Roux, Michael J. Sadowsky, Karen Schwarzberg Lipson, Matthew B. Sullivan, J. Gregory Caporaso and Rosa Krajmalnik-Brown

Background

Autism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity.

Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior.

Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily.

Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children.

Results

MTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks.

The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain.

Conclusions

This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact.

Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks).

———–

References

———–

 Video On Dr. Adam’s MTT Research – 10:57 min

————–

Forward This Audio Message Link To a Friend

http://corebrainjournal.com/214

———–

Thanks

Thanks, Dr. Adams,  for joining us here at CBJ to review these interesting insights regarding gut and brain connections in Autism Spectrum Disorders.

Have some feedback you’d like to share? Leave a note in the comment section below. If you enjoyed this episode, please share it using the social media buttons you see at the bottom of the post.

Also, please leave an honest review for the CoreBrain Journal Podcast on iTunes. Ratings and reviews are extremely helpful and much appreciated. Reviews do matter in the rankings of the show, and I read each one of them. Be counted.

If this post with these several references is helpful, please take a moment to pass it on.

Questions

In closing, if you have any questions, drop a comment on any posting here at CBJ, and I’ll get back to you. This discerning show of world-class experts is here for you, your families, and your clients – to tighten our collective dialogue for more precise answers.

Subscribe

And finally, don’t forget to subscribe to the show on iTunes to get automatic updates, or if you’re on an Android Device subscribe for timely updates at Google Play. Yes, these extraordinary experts with hundreds of years of combined experience are free.

————

Our Next CoreBrain Journal Episode

215 Dr. Kurt N. Woeller became a biomedical autism specialist many years ago in 1998. An original Defeat Autism Now! (DAN!) Referral physician, he has years of experience in researching and implementing advanced biomedical interventions based upon autism spectrum markers from laboratory testing, for individuals suffering from autism spectrum challenges. He now works as the Autism Outreach Clinical Director for Great Plains Laboratories in addition to his interesting treatment and training practice linked next.

His extensive network of exceedingly helpful educational websites, books and webinars provide parents of individuals on the autism-spectrum, as well as physicians and other healthcare providers treating autism at this link, access to an abundance of valuable information regarding the latest biomedical intervention systems – for parents at his Global Autism Summit.

About our mission, Dr Charles Parker

Our CBJ hosting objective is critical: upgrade mind and brain data through informed dialogue with neuroscience experts to build more predictable, more comprehensive, more understandable solutions for you and your family. Today's technology drives significantly improved mind-prognosis - beyond traditional psychiatric measures. Inaccurate labels, speculation, and guesswork are out - critical thinking, data, and measurement are in. Let's work together to connect advanced biomedical wisdom with everyday street reality. Start today. Advance informed care. Stay consistent. Subscribe here. Pass it on.

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.